US-based biopharmaceutical company Kezar Life Sciences has suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis.
The decision to suspend the trial was made following recommendations from an independent data monitoring committee (IDMC) after it had reviewed safety data from the trial.
According to the safety findings, four Grade Five (fatal) serious adverse events (SAEs) were reported during the trial in subjects enrolled in Argentina and the Philippines.
The IDMC's review indicated that three of the fatalities shared a pattern of symptoms and occurred close to the time of dosing.
https://finance.yahoo.com/m/5477554f-a83d-357a-852b-09dc038c51dd/kezar-life-sciences-suspends.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.